Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

Retrieved on: 2021-04-07 19:30:00

Tags for this article:

Medical specialties

Clinical medicine

Anatomy

Acquired hemolytic anemia

Thrombotic microangiopathy

Atypical hemolytic uremic syndrome

Hemolytic–uremic syndrome

Hemolysis

Click the tags to see associated articles and topics

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA. View article details on hiswai: https://www.onclive.com/view/weight-based-dosing-with-narsoplimab-is-recommended-in-hsct-tma

Excerpt

The endothelial injury occurs after the lectin pathway of complement is activated. Narsoplimab, a fully human IgG4 monoclonal antibody, inhibits MASP- ...

Article found on: www.onclive.com

View Original Article